Gastrointestinal functional bowel disorders: new therapies.
Present therapies for functional gastrointestinal disorders are symptomatic and mainly treat altered bowel habits. New therapies are focused on nerve-gut communication dysfunction: 5-HT3 antagonists and 5-HT4 agonists have demonstrated activity in clinical trials. Promising targets for upper gut dysmotility drugs are motilin and cholecystokinin A receptors. Tachykinins, calcitonin gene-related peptide or glutamate antagonists are the most relevant candidates for visceral pain.
Chovet
M
M
Institut de Recherche Jouveinal/Parke-Davis, Fresnes, France. maria.chovet@wl.com
D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D011964:Receptors, Gastrointestinal Hormone / Q000819:agonists; D011976:Receptors, Muscarinic / Q000378:metabolism; D018013:Receptors, Neuropeptide / Q000819:agonists; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use
D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D011964:Receptors, Gastrointestinal Hormone; D011976:Receptors, Muscarinic; D018013:Receptors, Neuropeptide; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C050802:motilin receptor